Cost–Utility Analysis of Multigene Assays to Guide Treatment Decisions for Node-Negative Early Breast Cancer
All four multigene assays were cost-effective from a societal perspective, offering low net lifetime costs or savings with improved outcomes compared with clinicopathologic risk assessment alone. These assays can help refine treatment decisions by providing prognostic risk estimates. In the case of the 21-gene assay, it can also predict chemotherapy benefit leading to the highest lifetime cost savings and greatest QALY gain.
Authors
- Yara George Abdou (ORCID: https://orcid.org/0000-0002-4827-8613)
- Jennifer M. Racz (ORCID: https://orcid.org/0000-0003-4176-5598)
- Christy Russell (ORCID: https://orcid.org/0000-0002-9303-9611)
- Yaneth Gil-Rojas (ORCID: https://orcid.org/0000-0002-9908-4878)
- Vladislav Berdunov (ORCID: https://orcid.org/0000-0002-5743-2184)
- Sara Campbell
- Gebra Cuyún-Carter
Institutions
- University of North Carolina Health Care (US)
- Exact Sciences (United States) (US)
- Paññāsāstra University of Cambodia (KH)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1007/s40487-024-00312-4
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.29